August 5, 2021 -- InvestorsHub NewsWire -- via NetworkNewsWire
Editorial Coverage: A leading
cause of death in the United States
for men and women of most racial and ethnic groups, heart disease
is a pervasive health challenge that destroys lives. The Centers
for Disease Control and Prevention (“CDC”) reports that one person
dies every 36 seconds from cardiovascular disease. Treating the
disease, as well as the conditions related to it such as high blood
pressure, or hypertension, is a top priority for those in the
medical space, and innovative companies are looking for ways to
provide even more effective treatments. A leader in hypertension
innovation, Lexaria Bioscience Corp. (NASDAQ:
LEXX) (Profile) is focused on using its
patented DehydraTECH(TM) drug delivery to identify safe and
affordable treatments to the approximately 108 million, or almost
one-half, of American adults dealing with high blood pressure.
Innovation is a key characteristic of any successful company
working in the pharma space, and other companies that are
recognized as innovation leaders include Jazz
Pharmaceuticals plc (NASDAQ:
JAZZ), Johnson & Johnson (NYSE:
JNJ), United Therapeutics
Corporation (NASDAQ:
UTHR) and Abbott Laboratories (NYSE:
ABT).
- Hypertension is a primary risk factor for heart disease, a
leading cause of death in the United States.
- Lexaria is an innovator in the space, developing potential
treatments utilizing its proprietary DehydraTECH technology.
- LEXX has identified three main areas to focus on, including
pharmaceuticals and the treatment of heart disease.
- Early reports from the company’s most recent human clinical
study show DehydraTECH technology demonstrated rapid, sustained
drop in blood pressure.
Click here to view the custom infographic of
the Lexaria Bioscience editorial.
Hypertension News Isn’t All Bad
While the CDC reports that nearly half of all adults in the
United States, or 108 million, have hypertension, only about 24% of
those have their condition under control. In fact, many don’t even
know they have it. Yet controlling blood pressure is critical to
good health.
High blood pressure is often a primary or cause of death in
almost 500,000 deaths a year, with hypertension
potentially doubling the
risk of a heart attack and quadrupling the chance of
having a stroke; the condition can also increase the chances of
heart failure, vision loss, renal disease, dementia, peripheral
artery disease and more. And it’s not just a problem for
“old-people”; nearly one in four adults between the ages of 20 to
44 have high blood pressure. In addition, high blood pressure costs
the United States about $131 billion each year.
But the news isn’t all bad. Hypertension can be managed
— and even cured — with proper diagnosis and treatment.
It should come as no surprise then that the global
anti-hypertensive drug market is projected to
grow from $24.17 billion in 2020 to $27.81 billion in
2025. Even with current hypertension drugs available, only 24% of
the 108 million people in the U.S. with high blood pressure have
their condition under control. It’s a market ripe for
innovation.
Drug-Delivery Platform Shows Exciting
Potential
Lexaria
Bioscience Corp. (NASDAQ:
LEXX) looks to be a leader in some of the most exciting
innovation happening in the treatment of high blood pressure. The
Kelowna, British Columbia-based company has identified, developed
and patented a new drug-delivery platform. The proprietary tech,
called DehydraTECH technology, has been proven to increase the
speed of onset, bioavailability and potency of a variety of
substances.
The mechanics involve combining an active pharmaceutical
ingredient (“API”) with fatty acid oil and then applying the mix to
carrier particles, which can be common ingredients such as tapioca
starch or gum arabic. Next, a patented dehydration synthesis
procedure is completed, resulting in a powder or liquid that can be
used in the desired final form factor, such as a pill, tablet,
chewable or oil.
Recognizing the potential for this new innovation, Lexaria has
worked with National Research Council of Canada, the biggest
R&D organization in the country, since 2017. The partnership
has focused on defining the qualities of DehydraTECH, including
that Nuclear Magnetic Resonance molecular characterization suggests
DehydraTECH does not change the chemical structure of an API it
delivers. This is essential when considering reliance on original
API safety data in developing novel delivery methods without
starting from scratch regarding the FDA process, which opens the
door to a faster path to market.
Bottom line, this means that DehydraTECH could make lower doses
of some substances more effective while potentially reducing side
effects. With this in mind, the company has identified three areas
in which to focus ongoing research and development; one of those
areas is pharmaceuticals
and the treatment of heart disease.
Early Study Results Confirm DehydraTECH
Promise
As part of that R&D, Lexaria recently released results from
a human clinical study using DehydraTECH technology that
indicated a rapid and
sustained drop in blood pressure along with excellent
tolerability. “We are very encouraged by these early results in our
2021 hypertension program,” said Lexaria CEO Chris Bunka.
“Lexaria’s technology enabled a rapid and sustained drop in blood
pressure, especially systolic pressure and particularly in stage 2
hypertensive volunteers.”
The early report noted that initial study results show a
reduction in blood pressure in both male and female volunteers; the
decrease was most pronounced in the first 10–50 minutes of the
study treatment, reinforcing pre-existing findings demonstrating
that DehydraTECH delivers superior performance over generic
controls. Lead investigator on the study Dr. Phil Ainslie reported
that “these early results are extremely promising in this at-risk
hypertensive population and provide a fundamental support for
expansion into more prolonged repeat dosing and future longer term
clinical trials.
Diversification Creates Widespread Interest
In addition to its work on heart disease and hypertension,
Lexaria is also studying the potential impact DehydraTECH might
have on reduced-risk noncombusted nicotine and improved antiviral
drug delivery. Several successes in the company’s diverse pipeline
have been reported, in including in the
antiviral program where DehydraTECH was used to process
compounds from leading drugs used for antiviral drugs for
SARS-CoV-2/COVID-19 and HIV/AIDS. This work holds particular
promise in the current treatment of COVID-19 as well as looking
forward and being better prepared in the future for future,
inevitable pandemic situations.
The potential for use in a diverse group of market opportunities
could create widespread interest in DehydraTECH possibilities. An
example is today’s antivirals market, particularly the COVID-19
pandemic and the circulating delta variant; the market is currently
estimated at $52.1 billion with projections to reach $66.7 billion
by 2025. And that is only the beginning; DehydraTECH’s versatility
points to many other potential applications, including human
hormones (e.g., testosterone and estrogen replacement, a $21.9
billion market); oral mucosal nicotine (global smokeless tobacco
products market valued at $13.6 billion in 2018), vitamin D3 ($1.1
billion market); PDE5 inhibitors ($4.4 billion market in 2014); and
non-steroidal anti-inflammatories ($15.6 billion market in
2019).
Success Follows Innovation in Pharma Space
Lexaria is leading the way in hypertension innovation, where
research and discovery could not only save lives but also deliver
significant profits. The $92.4
billion cardiovascular drug market generates billions of
dollars every year for successful drug makers. Other big pharma
companies are looking to innovate in other promising markets as
well.
Jazz
Pharmaceuticals plc (NASDAQ:
JAZZ) recently announced
the Health Canada approval and availability of
Vyxeos(R) for the treatment of adults with newly diagnosed
therapy-related AML or AML with myelodysplasia-related changes. A
cancer of the bone marrow and blood, Considered a rare disease, AML
affects approximately 1,100 men and women in Canada annually, and
though the number of AML cases continues to rise, current treatment
regimens have remained the same for decades until now. “As a
company dedicated to bringing life-changing medicines to market and
redefining possibilities, the approval of Vyxeos in Canada
represents Jazz’s promise of putting patients first,”
said Paul Petrelli, general manager of Jazz Pharmaceuticals
Canada Inc.
Johnson and Johnson Innovation, a division of Johnson &
Johnson (NYSE:
JNJ) dedicated to innovating in the medical
space, recently announced the
extension of the Johnson & Johnson Innovation Partnering
Office. The office is located at Monash University’s Clayton
Campus in Melbourne and works in collaboration with the Victorian
state government. This joint initiative between Johnson &
Johnson Innovation, the Victorian Government and Monash University
will be extended for approximately two years through June 30, 2023.
The agreement will allow the group to continue connecting with the
Victorian innovation ecosystem, nurturing and accelerating
innovative research, new product development and commercialization
for a global market.
United Therapeutics
Corporation (NASDAQ:
UTHR) announced in June that the U.S. Food and
Drug Administration (“FDA”) has accepted for
priority review its New Drug Application (“NDA”) for
Tyvaso DPI(TM) for the treatment of pulmonary arterial hypertension
and pulmonary hypertension associated with interstitial lung
disease. Tyvaso DPI is a next-generation, dry-powder formulation of
Tyvaso. If approved, Tyvaso DPI is expected to provide a more
convenient method of administration as compared with traditional
nebulized Tyvaso therapy.
Abbott (NYSE: ABT) received
clearance this week from the FDA for its latest optical
coherence tomography (“OCT”) imaging platform powered by the
company’s new Ultreon software. This innovative imaging software
combines OCT with artificial intelligence (“AI”) to provide
physicians an enhanced, comprehensive view of coronary blood flow
and blockages to assist physician decision-making and provide the
best pathway for treatment. The company’s Ultreon software
integrates with Abbott’s new Dragonfly OpStar imaging catheter and
PressureWire X guidewire to provide physicians access to a broad
set of tools to assess coronary blood flow and blockages and
improve treatment planning for patients.
Innovation — in the high blood pressure space as well as
other compelling sectors in the pharma world — has the potential to
deliver huge dividends. Most important, of course, is lives that
are literally saved and quality of life that is enhanced, but
triumph in billion-dollar markets can provide added incentive for
success.
For more information about Lexaria Bioscience
Corp., please visit Lexaria
Bioscience Corp.
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a financial news and
content distribution company, one of 50+ brands within
the InvestorBrandNetwork (“IBN”), that
provides: (1) access to a network of wire
solutions via InvestorWire to reach all target markets,
industries and demographics in the most effective manner
possible; (2) article and editorial
syndication to 5,000+ news outlets; (3)
enhanced press release solutions to ensure maximum
impact; (4) social media distribution via IBN
millions of social media followers; and (5) a
full array of corporate communications solutions. As a multifaceted
organization with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and
public companies that desire to reach a wide audience comprising
investors, consumers, journalists and the general public. By
cutting through the overload of information in today’s market, NNW
brings its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text
“STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW is a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertakes no
obligation to update such statements.
SOURCE: NetworkNewsWire
Editorial Coverage
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Sep 2023 to Sep 2024